Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India)
This article was originally published in PharmAsia News
Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India) Major Indian pharmaceutical companies tend to accept out-of-court settlements of patent suits because they realize they need a continuous revenue flow from business abroad. Ranbaxy Laboratories, Dr. Reddy's, Lupin, Ranbaxy, Sun Pharma and Wockhardt have reached settlements by suing U.S. drug makers where in the past they might have pressed their claims in court. Each of the settled cases has involved a deal to be announced later guaranteeing a continued flow of income through the U.S. maker. Industry experts say those agreements are a sign generics makers are becoming more mature. (Click here for more )
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.